Among these drugs, four drugs targeting ADRB3 are selected as possible therapeutic agents for the treatment of obesity, consistent with the biological process of “brown fat cell differentiation”. This evidence concerns the gene ADRB3 and obesity due to melanocortin 4 receptor deficiency.